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Background: CD133 has been identified as a putative cancer stem cell marker in colorectal cancer (CRC). However,
the clinical and prognostic significance of CD133 in CRC remains controversial.
Methods: Publications were identified which assessed the clinical or prognostic significance of CD133 in CRC up to
October 2012. A meta-analysis was performed to clarify the association between CD133 expression and clinical
outcomes.
Results: A total of 12 studies met the inclusion criteria, and comprised 3652 cases. Analysis of these data showed
that CD133 was not significantly associated with the depth of CRC invasion (odds ratio [OR] = 1.44, 95% confidence
interval [CI]: 0.77–2.68, Z = 1.15, P = 0.252) or tumor differentiation (OR = 0.63, 95% CI: 0.28–1.46, Z = −1.06,
P = 0.286). Also, there was no statistically significant association of CD133 with lymph node metastasis (OR = 1.16,
95% CI: 0.87–1.54, Z = 1.05, P = 0.315) or lymphatic invasion (OR = 1.08, 95% CI: 0.81–1.43, Z = 0.53, P = 0.594).
However, in identified studies, overexpression of CD133 was highly correlated with reduced overall survival (relative
risk [RR] = 2.14, 95% CI: 1.45–3.17, Z = 3.81, P = 0.0001).
Conclusions: CD133 may play an important role in the progression of CRC, and overexpression of CD133 is closely
related with poorer patient survival. If these findings are confirmed by well-designed prospective studies, CD133
may be a useful maker for clinical applications.
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Colorectal cancer (CRC) is one of the most common vis-
ceral malignancies and a leading cause of death world-
wide. Increasing evidence suggests that cancers,
including CRC, may be hierarchically organized, with
only a small population of cancer cells, termed cancer
stem cells (CSCs), possessing the potential to initiate
and sustain tumor growth and metastasis [1-3]. Further-
more, these cells are inert to toxic environmental agents
owing to their high expression of ABC transporters, re-
sistance to apoptosis, and efficient DNA repair mechan-
isms [4-6]. Thus, it is of major importance to investigate
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reproduction in any medium, provided the orimportant factors in determining the clinical outcomes
of cancer.
The cell surface marker CD133 (also known as promi-
nin-1) is a five-domain transmembrane molecule, and
has been identified as a putative CSC marker in various
cancers, including brain tumors, prostate carcinoma and
CRC [7-9]. Ricci-Vitiani et al. reported that CD133+
cells in CRC exhibited CSC properties in vitro and
in vivo, such as self-renewal and high tumorigenic po-
tential [10]. As few as 262 CD133+ CRC cells were able
to form a tumor in NOD/SCID mice, whereas 10,000
CD133- cells failed. These suggested that CSCs had the
ability to self-renew and to form the bulk of a tumor cell
population.
The clinical relevance of CD133 is as a putative CSC
marker in patients with CRC, where CSCs are thought to
contribute to tumor progression and therapy resistance.
Galizia et al. demonstrated that CD133 expression was
correlated with clinical outcomes [11]. Overexpression oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formation or poor clinicopathologic parameters in CRC.
However, Kojima et al. showed that CD133 expression
varied according to the histological type of cancer [12].
There is insufficient clinical data to confirm a clinical ap-
plication for CD133. In order to address controversial
issues, we performed a meta-analysis to determine the
association between CD133 expression and clinicopatho-
logic parameters.Materials and methods
Publication search
Publications were identified in the PubMed database
(http://www.ncbi.nlm.nih. gov/pubmed/) using the fol-
lowing search terms: “CD133”, “colon cancer” or “colo-
rectal cancer”, and “overall survival” or “OS”. Additional
relevant searches were identified by manually cross-
referencing abstracts of articles. Articles in this study
were published up to October 2012. Titles and abstracts
were evaluated to identify relevant publications, and the
full text version scanned. The criteria for inclusion were:
(1) articles dealing with CD133 expression and either
prognostic factors or overall survival (OS) of CRC; (2)
articles containing sufficient data to allow the estimation
of an odds ratio (OR) or a relative risk (RR) of OS; (3)
articles in the English language; and (4) articles pub-
lished as original research. Reviews, comments, dupli-
cated studies, and articles unrelated to our analysis were
excluded. Studies with fewer than 50 patients, follow-up
less than 2 years, and relevant articles using RT-PCR
were also excluded.
The following information was extracted from the
included papers: author, publication year, patient's coun-
try, tumor stage, number of patients, research technique







Coco Italy 2012 I–III IHC
Hongo Japan 2012 I–IV IHC
Zhang China 2012 II–III IHC
Xi China 2011 I–IV IHC
Lugli Switzerland 2010 I–IV Tissue microarray
Takahashi Japan 2010 I–IV IHC
Ong Australia 2010 I–IV Tissue microarray
Li China 2009 IIIB IHC
Horst Germany 2009 I–II IHC
Choi South Korea 2009 0–IV Tissue microarray
Wang China 2009 0–IV IHC
Kojima Japan 2008 I–IV IHCsite. Two major groups were created according to the ob-
jective. One clarified the association between CD133 ex-
pression and clinicopathological parameters, including
depth of invasion, degree of differentiation, lymph node
status and lymphatic invasion. Another group investi-
gated the association between CD133 expression and OS.Statistical analysis
The meta-analysis was performed as previously described
[13]. For ease of analysis, the following data of CD133 ex-
pression and clinicopathological factors were combined
into single categories: CD133-negative and low; T1 and T2
stages; T3 and T4 stages; and well and moderate differenti-
ation. ORs with 95% CI were used to evaluate the associ-
ation between CD133 expression and clinicopathological
factors, including depth of invasion, differentiation, lymph
node status and lymphatic invasion. Survival data were
extracted from original papers as described by Parmar
et al. [14]. Differences between CD133 expression and OS
were quantified using RR with 95% CI. Heterogeneity
across studies was evaluated with the Q test and P values.
ORs and RRs were calculated by a random-effects model
when the P value was less than 0.05. Otherwise, a fixed-
effects model was used. Sensitivity analyses were per-
formed to estimate the influence of individual studies on
the summary effect. Funnel plots and Egger’s regression
test was used to assess publication bias. Statistical analyses
were estimated using R/meta software. P values were two-
sided, with significance at P < 0.05.Results
Description of studies
A total of 12 publications met the criteria for this analysis
(Additional files 1 and 2) [12,15-25]. The total number of








137 Santa Cruz 100 > 5% Colon or Rectum
303 Miltenyi Biotec 100 > 5% Colon or Rectum
125 Novus 150 ≥Score 4 colon
201 Abcam 200 ≥Score 5 Colon or Rectum
1235 Cell Signaling 100 > 5% Colon or Rectum
151 Abcam 200 > 50% Colon or Rectum
501 Miltenyi Biotech 10 > 5% Colon or Rectum
104 Abcam 150 ≥5% Colon or Rectum
110 Cell Signaling 100 ≥50% Colon
523 Santa Cruz 50 – Colon or Rectum
73 Abcam 200 > 10% Rectal
189 Miltenyi Biotech 100 > 10% Colon or Rectum
Figure 1 Forrest plot of odds ratios (ORs) for the association of CD133 expression with depth of invasion.
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summarized in Table 1. Nine articles dealt with clinico-
pathological factors. Nine studies determined with OS.
Three studies only reported the association between
CD133 expression and clinicopathological factors without
OS analysis. There were mainly two kinds of methods
used to evaluate CD133 expression in CRC specimens:
immunohistochemistry (IHC) and tissue microarray.
Correlation of CD133 expression with clinicopathological
parameters
Nine studies assessed the relationship between CD133
phenotype and depth of invasion (Figure 1). The pooled
OR was 1.44 (95% CI: 0.77–2.68, Z = 1.15, P = 0.252 ran-
dom-effect), and there was no significant heterogeneity,
suggesting CD133 expression was not associated with
depth of invasion. Five studies investigated the relation-
ship between CD133 expression and degree of differenti-
ation (Figure 2). There was no statistically significant
association of CD133 and tumor differentiation (pooled
OR = 0.63, 95% CI: 0.28–1.46, Z = −1.06, P = 0.286 ran-
dom-effect). There was also no association between
CD133 expression and clinical parameters such as lymph
node metastasis (pooled OR = 1.16, 95% CI: 0.87–1.54,
Z = 1.05, P = 0.315 fixed-effect) (Figure 3) or lymphatic
invasion (pooled OR = 1.08, 95% CI: 0.81–1.43, Z = 0.53,
P = 0.594 fixed-effect) (Figure 4). Moreover, Egger’sFigure 2 Forrest plot of ORs for the association of CD133 expressiontest indicated that above clinicopathological parameters
showed no significant publication bias (Additional file 3).
Impact of CD133 expression on overall survival of
colorectal cancer
The meta-analysis was performed on nine studies (1581
patients) investigating the association of CD133 expres-
sion and OS. The pooled RR was calculated using the
methods described above. As the test for heterogeneity
was significant (P < 0.0001), a random-effect model was
used to calculate the RR. The presence of CD133 ex-
pression was highly correlated with poor OS (pooled
RR = 2.14, 95% CI: 1.45–3.17, Z = 3.81, P = 0.0001)
(Figure 5). This indicated that CD133 was an inde-
pendent prognostic factor in CRC. No significant pub-
lication bias was detected (Additional file 3), and the
explanatory variables did not significantly influence RR
estimates for OS (Additional file 4).
Discussion and conclusion
To our knowledge, the present meta-analysis is the first
English language study to systematically determine the
association between CD133 expression and CRC sur-
vival. As the prognostic and predictive significance of
the CD133 phenotype in CRC was controversial, a quan-
titative meta-analysis of the study outcomes was war-
ranted. Our analysis indicated that CD133 expressionwith tumor differentiation.
Figure 3 Forrest plot of ORs for the association of CD133 expression with lymph node metastasis.
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might be a marker for poor prognosis of CRC.
CD133 is the epitope of a glycosylated form of mem-
brane protein, and the physiological function of CD133
remains unknown. It was originally classified as a poten-
tial CSC marker in CRC. Ieta et al. reported that CRC
tissue had much higher CD133 protein expression than
that of normal tissue [26]. In our study, the data showed
that CD133 was not positively correlated to the depth of
invasion or degree of tumor differentiation. Although
lymph node metastasis and lymphatic invasion were
more common in cases with high CD133 than in those
with CD133-negative or low, the differences were not
statistically significant. Concerning the prognostic value
of CD133, a few papers reported significant associations
with CRC, and that CD133 might be considered as a
new marker to determine the stage and management of
CRC [20,27]. It is notable that this association is
observed in our meta-analysis of CD133 phenotype and
OS, suggesting that this marker can be developed for
clinical applications.
For future studies, co-expression of colorectal CSC
markers associated with patient survival may be more
meaningful for clinical application in CRC. Several stud-
ies have shown that CSC-related factors, including
ALDH1 and LGR5, are associated with cancer progres-
sion [28,29]. In addition, CSCs have major phenotypicFigure 4 Forrest plot of ORs for the association of CD133 expressionand functional heterogeneity which may help distinguish
them from cancer cells, and may be of potential benefit
in the development of anti-cancer therapies to improve
clinical outcomes [30].
Certain limitations exist in this meta-analysis. First,
OS was determined from unadjusted RRs in the pub-
lished papers, and RRs from the survival curves might
be less reliable than direct analysis of variance. Ideally,
measurements should be obtained directly from pub-
lished statistics and adjusted using other prognostic fac-
tors. Second, the patient populations were not uniform,
e.g., Choi et al. focused on patients with invasiveness
and differentiation of CRC [25], while all the patients in
the Ong et al. study received neoadjuvant chemotherapy
[19]. These differences might partly influence the signifi-
cance of the clinicopathological outcome in survival
analyses.
In summary, this meta-analysis indicated that CD133
expression was not associated with common clinical
parameters of CRC, such as depth of invasion, tumor
differentiation, lymph node metastasis and lymphatic
permeation. However, high CD133 expression was asso-
ciated with a worse outcome than CD133-negative or
-low expression, and CD133 was an independent factor
associated with reduced survival. Further studies of
CD133 and its potential as a marker for CRC prognosis
in clinic are warranted.with lymphatic invasion.
Figure 5 Forrest plot of relative risk (RR) for the association of CD133 expression with overall survival (OS). It showed that CD133 could
be an independent prognostic factor for OS in CRC patients.
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